Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial
31 Aug, 2022
Authors: Amuge P, Lugemwa A, Wynne B, Mujuru AH, Violari A, Kityo MC, Archary M, Variava E, White E, Turner MR, Shakeshaft C, Ali S, Nathoo JK, Atwine L, Liberty…
Read MorePopulation pharmacokinetics of unbound and total plasma dolutegravir concentrations in children ≥ 12 years old: A pharmacokinetic sub-study of the SMILE trial-PENTA17-ANRS 152
05 Aug, 2022
Authors: Abdalla S, Compagnucci A, Riault Y, Cressey T, Saidi Y, Chan M, Coelho A, Nolan A, Chalermpantmetagul S, Amuge P, Musiime V, Violari A, Cotton M, Volokha A, Bologna…
Read MoreVoluntary Consent to Research on HIV-infected Children in the CHAPAS-4 and ODYSSEY HIV Clinical Trials
29 Jul, 2022
Authors: Makumbi S, Bajunirwe F, Ford D, Turkova A, Lugemwa A, Musiime V, Gibb D, Tamwesigire K.I Presented at: International Workshop on HIV & Pediatrics 2022
Read MoreDolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial
21 Jul, 2022
Authors: Turkova A, Waalewijn H, Chan M, Bollen P, Bwakura-Dangarembizi M, Kekitiinwa A, Cotton M, Lugemwa A, Variava E, Ahimbisibwe MG, Srirompotong U, Mumbiro V,Amuge P, Zuidewind P, Ali S,…
Read MoreBorrowing information across patient subgroups in clinical trials, with application to a paediatric trial
21 Feb, 2022
Authors: R.M. Turner, A Turkova, C.L. Moore, A Bamford, M Archary, L.N. Barlow-Mosha, M.F. Cotton, T.R. Cressey, E Kaudha, A Lugemwa, H Lyall, H.A. Mujuru, V Mulenga, V Musiime, P…
Read MoreDolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial
21 Feb, 2022
Authors: H Waalewijn, M.K Chan, P.D.J Bollen, H.A Mujuru, S Makumbi, A.R Kekitiinwa, E Kaudha, T Sarfati, G Musoro, A Nanduudu, A Lugemwa, P Amuge, C.L Moore, P Rojo, C…
Read MoreDolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children
30 Dec, 2021
Authors: A Turkova, E White, HA. Mujuru, AR. Kekitiinwa, CM. Kityo, A Violari, A Lugemwa, TR. Cressey, P Musoke, E Variava, MF. Cotton, M Archary, et al for the ODYSSEY Trial…
Read MoreDolutegravir-based ART is superior to standard of care ART in young children <14kg living with HIV
11 Dec, 2021
Authors: Kaudha E on behalf of the ODYSSEY trial Presented at: PEPFAR Uganda Science Summit
Read MoreDolutegravir-based ART is superior to NNRTI- and PI-based ART in infants, children and adolescents living with HIV (combined results of the main trial and the ‘under 14kg’ cohort)
28 Sep, 2021
Authors: Anna Turkova on behalf of the ODYSSEY trial team Presented at: CHIVA 2021
Read MoreVirological failures and genotypic resistance in children and adolescents randomised to dolutegravir-based ART vs. standard-of-care in the main ODYSSEY trial (≥14kg)
03 Sep, 2021
Authors: White E and Kityo C on behalf of the ODYSSEY trial team Presented at: CHIVA 2021
Read MoreNo age-related difference in dolutegravir metabolic glucuronidation ratio in children between 3 months and 18 years old in the ODYSSEY trial
29 Jul, 2021
Authors: T.G Jacobs, A. Colbers, H. Waalewijn, P. Amuge, D. Bbuye, E. Kaudha, A. Nanduudu, S. Makumbi, L. Atwine, S. Mudzingwa, K. Nathoo, J. Hakim, A. Liberty, A.J. Van Rensburg,…
Read MoreEffect of dolutegravir on folate and vitamin B12 status among HIV- infected children and adolescents in the ODYSSEY trial
29 Jul, 2021
Authors: L. Barlow-Mosha, G. Ahimbisibwe, E. Chappell, P.M. Amuge, A. Nanduudu, E. Kaudha, T. Amukele, D. Balamusani, B. Kafufu, A. Nimwesiga, C. Kityo, A.R Kekitiinwa, R. Namwanje, G. Kasangaki, A.…
Read MoreVirological failures and genotypic resistance in children and adolescents randomised to dolutegravir-based ART vs. standard-of-care in the ODYSSEY trial
29 Jul, 2021
Authors: E White, A Turkova, HA Mujuru, I Nankya, B Wynne, S Ali, A Kekitiinwa, A Lugemwa, E Kaudha, A Liberty, H Cassim, M Archary, M Cotton, L Barlow-Mosha, TR…
Read MoreDolutegravir-based ART is superior to NNRTI- and PI-based ART in infants, children and adolescents living with HIV (combined results of the main trial and the ‘under 14kg’ cohort)
29 Jul, 2021
Authors: Turkova A on behalf of the ODYSSEY trial team Presented at: CHIVA 2021
Read MoreNeuropsychiatric manifestations and sleep disturbances in children and adolescents randomised to dolutegravir-based ART vs standard-of-care in the ODYSSEY trial
29 Jul, 2021
Authors: A Turkova, A Kekitiinwa, E White, V Mumbiro, E Khauda, A Liberty, E Dobbels, GM Ahimbisibwe, T Moloantoa, L Atwine, S Kanjanavanit, NR Mosia, T Puthanakit, T Smit, R…
Read MoreNeuropsychiatric manifestations and sleep disturbances in children and adolescents randomised to dolutegravir-based ART vs standard-of-care in the ODYSSEY trial
29 Jul, 2021
Authors: Violari A, Kekitiinwa A, White E, Mumbiro V, Rutebarika D, Dobbels E, Kataike H, Moloantoa T, Atwine L, Nazzinda R, Mbabazi R, Kanjanavanit S, Mosia N, Na-Rajsimax S, Techakunakorn…
Read MoreEffect of dolutegravir on folate and vitamin B12 status among HIV- infected children and adolescents in the ODYSSEY trial
29 Jul, 2021
Authors: L. Barlow-Mosha, G. Ahimbisibwe, E. Chappell, P.M. Amuge, A. Nanduudu, E. Kaudha, T. Amukele, D. Balamusani, B. Kafufu, A. Nimwesiga, C. Kityo, A.R Kekitiinwa, R. Namwanje, G. Kasangaki, A.…
Read MoreDolutegravir-Based ART is Superior to Standard of Care in Young Children Living With HIV
29 Jul, 2021
Authors: P Amuge on behalf of the ODYSSEY trial team Published in: International workshop on HIV pediatrics 2021 Abstract Background: ODYSSEY, a multi-country randomised trial, demonstrated superior treatment efficacy…
Read More